GraphiteRx’s Post

Check out our latest blog post if you're interested in learning about some of the downstream effects of CMS's Drug Price Negotiation Program. Thanks to Scott Briggs and Matthew Riordan for the partnership on this!

Kimberly Westrich (Chief Strategy Officer, National Pharmaceutical Council) shares her highlights in US healthcare value and access from July and August 2024. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #hta #healthtechnologyassessment #healthdata #healthpolicy #valueassessment #inflationreductionact

Enhancing Patient Outcomes: The Role of Long-Term Care Facilities for Pharma Manufacturers. There are significant opportunities for pharmaceutical companies, particularly those offering high-quality, branded medications. Many patients in long-term care are dual-eligible for Medicare and Medicaid, so they don’t pay out-of-pocket for medications. This often leads to a preference for branded drugs over generics. Stay ahead with cutting-edge insights from Life Sciences by PointClickCare —follow us on LinkedIn. #Pharmaceuticals #LongTermCare #Healthcare #MedicareMedicaid

With the burdens of complex, chronic and rare diseases continuing to rise, improving access to specialty pharmaceutical products has become a critical necessity. Yet, manufacturers continue to contend with distribution barriers, operational inefficiencies, and infrastructural limitations, leaving many patients struggling to obtain the breakthrough treatments they need. At AscellaHealth, we offer transformative solutions to help pharmaceutical stakeholders overcome these barriers. We believe that every patient, including those in small populations dealing with complex conditions, should have access to life-changing specialty therapies when and where they need them. Read more in our latest article: https://lnkd.in/e9qXBG2p   #AscellaHealth #LifeSciences #PatientCentricSolutions #SpecialtyPharma #HealthcareInnovation #RareDisease

Wondering what Medicare drug price negotiation means for the commercial insurance market? Check out this free webinar for an insightful conversation between John O'Brien and Shawn Gremminger. #employersponsoredinsurance #ira #medicaredrugpricenegotiation

We continue to help clients navigate the complexities surrounding the #InflationReductionAct. Today, our experts are diving into the anticipated effects of the IRA on payer contracting. While the Inflation Reduction Act will lower costs for CMS and patients, it is also likely to cause a range of second-order effects on the pharmaceutical industry, primarily around R&D investments and payer contract dynamics. How should the pharmaceutical industry be preparing for these shifts? Learn more from Thomas Marder, Matthew Riordan, and Scott Briggs in our latest piece here: https://lnkd.in/eXZMa5Xe #Pharma #IRA #Healthcare #Payers

As the first round of MFP negotiations approach their conclusions this summer a next round of negotiations await with payers who will be armed with public knowledge of MFP levels. How will this impact contracting for MFP-negotiated products and for their competitors? Learn about our perspective on this emerging topic here:

It is here, and it is real. The #inflationreductionact, learn more how to navigate the various complex dynamics from our experts, Scott Briggs, Thomas Marder, Matthew Riordan

Spread Pricing, a common practice in the pharmaceutical industry, has significant implications for drug costs and patient care. This practice involves Pharmacy Benefit Managers (PBMs) charging payers more for prescription drugs than what they pay pharmacies, pocketing the price difference as profit. Many consider spread pricing to be anticompetitive, contributing to higher drug costs and potentially compromising patient outcomes. In contrast, pass-through pricing offers an alternative approach that may have its own advantages. In light of the challenges posed by spread pricing, some clients remain hesitant to embrace change, despite the potential benefits of exploring alternative pricing strategies. Addressing these concerns and understanding the nuances between spread pricing and pass-through pricing is crucial for managing drug costs effectively and ensuring optimal care for patients. #PharmacyBenefitManagers #DrugCosts #Healthcare #PatientCare #PricingStrategies

💡 The rise of biosimilars is revolutionizing pharmacy billing! With lower costs and increasing demand, they’re reshaping reimbursement strategies and patient access. 💊💰 Stay ahead of the curve by understanding how biosimilars are transforming the pharmaceutical landscape. #PharmacyBilling #Biosimilars #HealthcareInnovation #RevenueCycleManagement #BillingTrends #PharmaInsights #HealthcareRCM #CathodeHealthcare #PharmacyTrends